Halozyme Therapeutics, Inc. (HALO) Revenue by Segment
Halozyme Therapeutics revenue by segment at a glance
In Q2 fiscal 2026 (the quarter ended June 30, 2026), Halozyme Therapeutics's largest product or service was Royalty, with $307.70 million or 64% of revenue, up 49.6% from a year earlier. Next: Product (27%) and Collaborative Agreements (9%).
The fastest-growing product or service from a year earlier was Product (+59.0%).
From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q1 fiscal 2018.
Halozyme Therapeutics, Inc.
HALO
Healthcare
Revenue breakdown
Fiscal quarters, from company filings
Halozyme Therapeutics revenue by product or service, last 4 quarters
| Product or service | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Royalty | $307.7M | $240.7M | $236.0M | $205.6M | 64% |
| Product | $129.6M | $130.4M | $94.2M | $81.5M | 27% |
| Collaborative Agreements | $43.7M | $5.6M | – | $38.6M | 9% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Questions and answers
Which product or service makes the most money for Halozyme Therapeutics?
Royalty: $307.70 million, or 64% of revenue, in Q2 fiscal 2026.
What are Halozyme Therapeutics's main products and services?
By revenue in Q2 fiscal 2026: Royalty (64%), Product (27%) and Collaborative Agreements (9%).
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
